Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women

Mary Kate Shapley-Quinn, Nicole Laborde, Ellen Luecke, Craig Hoesley, Robert A Salata, Sherri Johnson, Annalene Nel, Lydia Soto-Torres, Beatrice A Chen, Ariane van der Straten, Mary Kate Shapley-Quinn, Nicole Laborde, Ellen Luecke, Craig Hoesley, Robert A Salata, Sherri Johnson, Annalene Nel, Lydia Soto-Torres, Beatrice A Chen, Ariane van der Straten

Abstract

For women in the United States who remain sexually active beyond child-bearing years, susceptibility to HIV infection remains, yet condom use is low. We assessed acceptability of the dapivirine vaginal ring (ring) among 96 postmenopausal US women enrolled in a placebo-controlled multisite phase II trial of the ring, using questionnaires and in-depth interviews. Three quarters of women reported "perfect" adherence (ring never out) over the 3-month trial period. At study exit, the ring was found to be very easy to use by 72%, very comfortable to wear by 65%, and 4% reported it ever interfered with their daily activities. The most common worries among participants at preinitiation had decreased significantly at study exit (e.g., worries about inserting the ring declined from 46% to 6%, discomfort during daily activities from 53% to 3%, ring not staying in place from 48% to 14%, all p < 0.0001). Despite some couples feeling the ring during sex, the ring was perceived as more suitable than condoms for prevention because it was not burdensome to use, did not interfere with erection, and provided (for some) additional vaginal lubrication. The ring is a promising, highly acceptable HIV prevention method that is suitable to the lives of postmenopausal women and their male partners and can provide them with an additional prevention choice. Clinical Trials Registration: NCT02010593.

Keywords: acceptability and preference; dapivirine; intravaginal ring; microbicides; postmenopausal; pre-exposure prophylaxis.

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.
FIG. 1.
Dapivirine ring and dimensions.
FIG. 2.
FIG. 2.
McNemar test: *p < 0.05, ***p < 0.0001. Changes in ring worries from baseline to month 3 (exit visit).
FIG. 3.
FIG. 3.
n = 47. Ring use experience during sex (month 3).

References

    1. UNAIDS. Fact sheet 2021: Global HIV Statistics. Available at: (Last accessed October 11, 2021).
    1. Centers for Disease Control and Prevention. HIV and older Americans. Available at: (Last accessed November 23, 2020).
    1. Autenrieth CS, Beck EJ, Stelzle D, et al. . Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000–2020. PLoS One 2018;13:e0207005.
    1. Karpiak SE, Lunievicz JL. Age is not a condom: HIV and sexual health for older adults. Curr Sex Health Rep 2017;9:109–115.
    1. Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV infection and older Americans: The public health perspective. Am J Public Health 2012;102:1516–1526.
    1. Meditz AL, Moreau KL, MaWhinney S, et al. . CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women. J Acquir Immune Defic Syndr 2012;59:221–228.
    1. Rollenhagen C, Asin SN. Enhanced HIV-1 replication in ex vivo ectocervical tissues from post-menopausal women correlates with increased inflammatory responses. Mucosal Immunol 2011;4:671–681.
    1. Thurman AR, Yousefieh N, Chandra N, et al. . Comparison of mucosal markers of human immunodeficiency virus susceptibility in healthy premenopausal versus postmenopausal women. AIDS Res Hum Retroviruses 2017;33:807–819.
    1. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992;304:809–813.
    1. U.S. Food & Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. 2020. Available at: (Last accessed January 11, 2022).
    1. Riddell J, IV, Amico KR, Mayer KH. HIV preexposure prophylaxis: A review. JAMA 2018;319:1261–1268.
    1. Celum CL, Delany-Moretlwe S, Baeten JM, et al. . HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: From efficacy trials to delivery. J Int AIDS Soc 2019;22 Suppl 4:e25298.
    1. Spinelli MA, Buchbinder SP. Pre-exposure prophylaxis persistence is a critical Issue in PrEP implementation. Clin Infect Dis 2020;71:583–585.
    1. Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: A narrative review. Adv Ther 2020;37:1778–1811.
    1. Huang Y-LA, Tao G, Smith DK, Hoover KW. Persistence with human immunodeficiency virus pre-exposure prophylaxis in the United States, 2012–2017. Clin Infect Dis 2020;72:379–385.
    1. Blackstock OJ, Patel VV, Felsen U, et al. . Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care 2017;29:866–869.
    1. Fonner VA, Dalglish SL, Kennedy CE, et al. . Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (London, England) 2016;30:1973–1983.
    1. Hanscom B, Janes HE, Guarino PD, et al. . Brief Report: Preventing HIV-1 infection in women using oral preexposure prophylaxis: A meta-analysis of current evidence. J Acquir Immune Defic Syndr 2016;73:606–608.
    1. van der Straten A, Shapley-Quinn MK, Reddy K, et al. . Favoring “Peace of Mind”: A qualitative study of African women's HIV prevention product formulation preferences from the MTN-020/ASPIRE trial. AIDS Patient Care STDS 2017;31:305–314.
    1. Baeten JM, Palanee-Phillips T, Brown ER, et al. . Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med 2016;375:2121–2132.
    1. Nel A, van Niekerk N, Kapiga S, et al. . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med 2016;375:2133–2143.
    1. Baeten JM, Palanee-Phillips T, Mgodi NM, et al. . Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): An open-label, extension study. Lancet HIV 2021;8:e87–e95.
    1. Nel A, van Niekerk N, Van Baelen B, et al. . Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): An open-label, extension study. Lancet HIV 2021;8:e77–e86.
    1. Brown ER, Hendrix CW, van der Straten A, et al. . Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: A secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc 2020;23:e25634.
    1. Griffin JB, Ridgeway K, Montgomery E, et al. . Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis. PLoS One 2019;14:e0224898.
    1. IPM. Dapivirine Ring. Available at: (Last accessed November 18, 2021).
    1. National Institutes of Health. Vaginal ring for HIV prevention receives positive opinion from European regulator. Available at: (Last accessed November 23, 2020).
    1. World Health Organization. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. Available at: (Last accessed October 11, 2021).
    1. Chen BA, Zhang J, Gundacker HM, et al. . Phase 2a safety, pharmacokinetics, and acceptability of dapivirine vaginal rings in US postmenopausal women. Clin Infect Dis 2019;68:1144–1151.
    1. Heinemann K, Ruebig A, Potthoff P, et al. . The Menopause Rating Scale (MRS) scale: A methodological review. Health Qual Life Outcomes 2004;2:45.
    1. Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP trials: Current status and a reconceptualization. Curr Opin HIV AIDS 2012;7:534–541.
    1. van der Straten A, Browne EN, Shapley-Quinn MK, et al. . First impressions matter: How initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr 2019;81:304–310.
    1. Nel A, Bekker LG, Bukusi E, et al. . Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa. PLoS One 2016;11:e0147743.
    1. van der Straten A, Panther L, Laborde N, et al. . Adherence and acceptability of a multidrug vaginal ring for HIV prevention in a Phase I Study in the United States. AIDS Behav 2016;20:2644–2653.
    1. Husnik MJ, Brown ER, Dadabhai SS, et al. . Correlates of adherence to the dapivirine vaginal ring for HIV-1 prevention. AIDS Behav 2021;25:2801–2814.
    1. Ridgeway K, Montgomery ET, Smith K, et al. . Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world. Contraception 2022;106:16–33.
    1. Calabrese SK, Galvao RW, Dovidio JF, et al. . Contraception as a potential gateway to pre-exposure prophylaxis: US women's pre-exposure prophylaxis modality preferences align with their birth control practices. AIDS Patient Care STDS 2020;34:132–146.
    1. Watkins ES. The construction of a construction of a contraceptive technology: An investigation of the meanings of norplant. Sci Technol Human Values 2011;36:33–54.
    1. Black K, Lotke P, Buhling KJ, et al. . A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women. Eur J Contracept Reprod Health Care 2012;17:340–350.
    1. Montgomery ET, Katz AWK, Duby Z, et al. . Men's sexual experiences with the dapivirine vaginal ring in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav 2021;25:1890–1900.
    1. Pleasants E, Tauya T, Reddy K, et al. . Relationship type and use of the vaginal ring for HIV-1 prevention in the MTN 020/ASPIRE trial. AIDS Behav 2020;24:866–880.
    1. Laborde ND, Pleasants E, Reddy K, et al. . Impact of the dapivirine vaginal ring on sexual experiences and intimate partnerships of women in an HIV prevention clinical trial: Managing ring detection and hot sex. AIDS Behav 2018;22:437–446.
    1. McGowan I, Taylor DJ. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies. Sex Transm Dis 2010;37:361–364.
    1. Peebles K, van der Straten A, Palanee-Phillips T, et al. . Brief Report: Anal intercourse, HIV-1 risk, and efficacy in a trial of a dapivirine vaginal ring for HIV-1 prevention. J Acquir Immune Defic Syndr 2020;83:197–201.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe